QOP
SPRY icon

Quinn Opportunity Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Quinn Opportunity Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Hold
155,000
– – 0.06% 197
2025
Q4 		$1.81M Buy
155,000
+30,000
+24% +$292K 0.08% 185
2025
Q3 		$1.26M Buy
125,000
+80,000
+178% +$1.15M 0.09% 169
2025
Q2 		$785K Sell
45,000
-66,628
-60% -$961K 0.07% 208
2025
Q1 		$1.4M Buy
+111,628
New +$1.34M 0.1% 187

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Quinn Opportunity Partners's SPRY Position: Q1 2026 in Review

Quinn Opportunity Partners held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 155,000 shares worth $1.24M. The position accounts for 0.06% of the portfolio, ranked #197.

Quinn Opportunity Partners first reported a position in SPRY in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.81M in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Quinn Opportunity Partners held 155,000 shares of ARS Pharmaceuticals worth $1.24M as of Q1 2026.
  • Quinn Opportunity Partners left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up 0.06% of Quinn Opportunity Partners's portfolio in Q1 2026, its #197 holding.
  • Quinn Opportunity Partners first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Quinn Opportunity Partners's ARS Pharmaceuticals position peaked at $1.81M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.